ZoonCo

A safe, affordable platform for personalized cancer treatment in pets.


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9


ZOONCO: FAST FACTS

ZoonCo makes better patients by precisely and safely heating cancerous tumors in a way that activates the body’s immune system against a patient’s specific cancer. The ZoonCo treatment utilizes precision-controlled intracellular hyperthermia that can be used alongside other immuno-oncology, surgical, chemo, or radiological treatments or as a minimally invasive stand-alone therapy with minimum to no side effects.


LOSING A PET TO CANCER


CHANGING THE PET
CANCER PARADIGM

ZoomCo’s immune-activation approach is not harmful in its application and it doesn’t disrupt the animal’s quality of life. There are no toxic or lingering effects from the treatment and the patient is able to continue its normal routine immediately after treatment.

We provide a local treatment that builds a destructive army that seeks distant — and often undiagnosed — tumor cells.

Best of all, our therapy can provide immunity against recurrence of that specific cancer.

We believe that our “better patient” platform will change the paradigm of cancer care for all animals.


KEY FEATURES / HOW IT WORKS


TRACTION & ACCOMPLISHMENTS

PRODUCT DEVELOPMENT
The ZoonCo treatment model requires an AMF medical device and injectable nanoparticles. More than $5 million has been spent to date on developing the current AMF generator and clinical-grade injectable. We are working on manufacturing an updated commercial model in anticipation of our future markets and rollout strategy.

CUSTOMER ACCEPTANCE
There has been widespread enthusiasm for the approach that ZoonCo is bringing to the companion animal cancer market. However, two things are required to convert acceptance into reality: data and regulatory approval. These two items are conjoined, and the purpose of the current fundraise is to scale up approved manufacturing and distribution so that both our equipment and injectable material are ready to be shipped to customers.


MEET THE TEAM

ALDEN PRITCHARD
FOUNDER AND CEO
With more than 30 years of leadership and entrepreneurial experience, he founded and has successfully led Kaio Therapy for seven years in commercializing intracellular hyperthermia treatment for human cancer. He has been responsible for strategy development and implementation, technology procurement, and has owned, partnered or operated businesses in Japan, China, Russia, France and Poland. He received his B.A.from the University of North Carolina - Chapel Hill and Executive MBA from The College of William & Mary.

JENNIFER TURNAGE
CFO
Turnage began her career with PricewaterhouseCoopers. She has since served as the CFO of eight investor-backed startups with five successful exits and was a finalist for the Triangle Business Journal’s CFO of the Year Award. Jennifer was a 2013 winner of the TBJ’s Women in Business award for her first entrepreneurial venture, the fractional professional services firm TechCXO RTP. In 2019, Jennifer was recognized as a winner of the Wilmington Business Journal’s Coastal Entrepreneur Award in the internet category. As Co-founder and CEO of myBeeHyve, she was selected for an NC IDEA SEED grant and the NC IDEA SOAR program for female entrepreneurs and was a nominee for the Cape Fear Region YWCA Women on Achievement Award.

DR. DAVE RUSLANDER
CSO
Dr. David Ruslander received his veterinary degree from Cornell University and began his career as an intern at the Western College of Veterinary Medicine in Saskatoon, Canada. Dr. Ruslander developed an early interest in oncology and completed a medical oncology residency at the Tufts University School of Veterinary Medicine. A desire for continued learning took him to the University of Zurich in Switzerland where he worked as an oncologist and received training in radiation oncology. Dr. Ruslander was on the faculty at Tufts from 1997-2000 and then at NCSU from 2000-2004 before joining VSH. He is a past president of the Veterinary Cancer Society. Dr. Ruslander is board certified in both medical and radiation oncology. His primary interests involve their roles in the multimodality management of the veterinary cancer patient.

 

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.